IMRX 最新10-Q变化
将 IMRX 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-10-29 与上一份 10-Q · 2026-08-05
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +13 | −11 | ~27 | 81 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 1 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 风险因素 | 部分风险因素更新 | +4 | −3 | ~9 | 542 |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 2 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-10-29
•in the first half of 2027, providing additional data from the Phase 2 mGnP Arm;
We expect our general and administrative expenses will increase for the foreseeable future if and as we continue to increase our general and administrative headcount to support our continued research and development activities and, if any product candidates receive marketing approval, commercializat…
Comparison of the Three Months Ended September 30, 2026 and 2025
General and administrative expenses increased by approximately $0.6 million, or 12.3%, to approximately $5.1 million for the three months ended September 30, 2026, as compared to approximately $4.5 million for the three months ended September 30, 2025. The increase of approximately $0.6 million was …
Comparison of the Nine Months Ended September 30, 2026 and 2025
相对上期删除的文字 · 来源:10-Q · 2026-08-05
available third-party MPACT pivotal trial data for gemcitabine/nab-paclitaxel. Our Phase 1/2a clinical trial of atebimetinib does not include a head-to-head comparison against any other agents, and caution should be exercised when comparing data across trials.
We expect our general and administrative expenses will increase for the foreseeable future if and as we continue to increase our general and administrative headcount to support our continued research and development activities and, if any product candidates receive marketing approval, commercializat…
also expect to continue to incur increased expenses associated with operating as a public company, including costs related to accounting, audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and rules and regulations of the Securities and Ex…
General and administrative expenses increased by approximately $0.7 million, or 16.3%, to approximately $5.0 million for the three months ended June 30, 2026, as compared to approximately $4.3 million for the three months ended June 30, 2025. The increase of approximately $0.7 million was primarily …
During the six months ended June 30, 2026, operating activities used approximately $34.9 million of cash, primarily resulting from our net loss of approximately $30.7 million, changes in assets and liabilities of $6.9 million, and accretion of discount of marketable securities of $0.9 million. This …
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-10-29
Additionally, if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result. For example, the FDA could require us to adopt a REMS to ensure that t…
risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and costlier than what is typical for the industry…
•we may be forced to suspend marketing of that product, or be forced to or decide to remove the product from the marketplace;
•the efficacy and safety profile as demonstrated in our clinical trials compared to alternative treatments, which alternative treatments could impact the interpretability of data from such clinical trials (including, without limitation, MAPKeeper 301);
相对上期删除的文字 · 来源:10-Q · 2026-08-05
Additionally, if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result. For example, the FDA could require us to adopt a REMS to ensure that t…
•we may be forced to suspend marketing of that product, or be forced to or decide to remove the product form the marketplace;
•the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments;
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议